1262 (1262) Fair Value & Analysis

Consumer Defensive · Market cap HK$577M

1 1262 1262 · HK

PriceHK$2.38

Fair ValueHK$0.9700

Upside-59.2%

Quality40/100

Evidence: High Range HK$0.7300 – HK$1.26

Fair value as of: Jul 2, 2026

From 16 valuation models · updated today

Share price −4.8% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$1.58 – HK$4.62 · fair‑value band HK$0.7300 – HK$1.26 · the HK$2.38 price screens above the HK$0.9700 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1262 (1262) currently trades at HK$2.38, while our model-based Fair Value estimate is HK$0.9700 — implying the stock looks roughly 59.2% overvalued today. We read business quality at 40/100 (below-average quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 1262 generated revenue of HK$970M at a net margin of 1.2%. Revenue grew 21.7% year over year. It earns a return on equity of 5.4%. Net debt stands at HK$448M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$970M

Revenue growth (YoY) +21.7%

Net margin 1.2%

Return on equity 5.4%

Free cash flow −HK$50.6M FY2025

P/E ratio 40.2

More key figures

Operating margin 4.7%

EPS (TTM) HK$0.0100

Net debt HK$448M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1262 reported revenue of HK$970M in FY2025 versus HK$648M in FY2021, a compound +10.6%/yr. Reported net income was HK$11.9M in FY2025.

Revenue +10.6%/yr

FY21 HK$648M

FY22 HK$684M

FY23 HK$764M

FY24 HK$867M

FY25 HK$970M

Net income

FY21 −HK$65.2M

FY22 −HK$75.3M

FY23 −HK$105M

FY24 −HK$93.5M

FY25 HK$11.9M

Is 1262 fairly valued? → Check now

Similar stocks

6 more Packaged Foods stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Nestlé S.A NESN	CHF 79.00	CHF 57.28	-27%
Foshan Haitian Flavouring and Food Company 603288	¥35.10	¥25.34	-28%
Nestlé India Limited NESTLEIND	₹1,438	₹362.37	-75%
Grupo Bimbo, S.A. BIMBOA	57.10 MXN	72.19 MXN	+26%
Uni-President Enterprises Corp 1216	75.10 TWD	72.54 TWD	-3%
Britannia Industries Limited BRITANNIA	₹5,218	₹3,567	-32%

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1262 (1262) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.9700 versus a price of HK$2.38 — about −59% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 1262?

Our model-based fair value for 1262 is HK$0.9700 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$2.38.

What is the quality score of 1262?

1262 has a Quality Score of 40/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1262 (1262)?

1262 reported trailing-twelve-month revenue of about HK$970M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1262?

The net profit margin of 1262 is about 1.2%, meaning it keeps roughly 1.2% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.